These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 16019253)
1. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Catley L; Tai YT; Chauhan D; Anderson KC Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253 [TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479 [TBL] [Abstract][Full Text] [Related]
3. [Role of bortezomib in the treatment of multiple myeloma]. Gotoh A; Ohyashiki K Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Bladé J; Cibeira MT; Rosiñol L Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077 [TBL] [Abstract][Full Text] [Related]
5. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
6. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib in combination with other therapies for the treatment of multiple myeloma. Orlowski RZ J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424 [TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition and multiple myeloma. Kanagasabaphy P; Morgan GJ; Davies FE Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
14. New drugs in multiple myeloma. Berenson JR; Yellin O Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422 [TBL] [Abstract][Full Text] [Related]
15. Melphalan and its role in the management of patients with multiple myeloma. Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453 [TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related]
18. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Ciepłuch H; Baran W; Hellmann A Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079 [TBL] [Abstract][Full Text] [Related]
19. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697 [TBL] [Abstract][Full Text] [Related]
20. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]